Form 4: Travere CFO Sells Shares Under Pre-Arranged 10b5-1 Plan

Travere Therapeutics' CFO, Christopher R. Cline, sold common stock totaling 1,745 shares on February 4, 2026, under a pre-arranged 10b5-1 plan.

Summary

• Christopher R. Cline, Chief Financial Officer of Travere Therapeutics, Inc. (TVTX), reported transactions involving the sale of common stock.
• On February 4, 2026, Mr. Cline sold 1,635 shares of common stock at a weighted average price of $32.14 per share.
• The price range for the 1,635 shares sold was between $31.645 and $32.645.
• Also on February 4, 2026, an additional 110 shares of common stock were sold at a price of $32.9 per share.
• These sales were executed pursuant to a Rule 10b5-1(c) written plan adopted on May 28, 2025.
• The sales included shares to cover tax obligations incurred upon the vesting of restricted stock units.
• Following these reported transactions, Mr. Cline beneficially owns 111,226 shares of Travere Therapeutics common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine insider transaction under a pre-established plan, which typically has a neutral impact on market sentiment as it is often for personal financial management or tax purposes rather than a reflection of company performance.

Industry Context

StockSavvy.ai notes that insider sales executed under Rule 10b5-1 plans are a common practice for corporate executives to manage personal financial planning and tax liabilities. These plans are pre-arranged to allow insiders to sell shares at a predetermined time or price, thereby providing an affirmative defense against claims of trading on material non-public information. This particular filing represents a routine disclosure of such a transaction.

Stakeholder Impact

• Shareholders may note the reduction in the CFO's direct ownership, but given the sale was pre-planned and partly for tax obligations, the impact on investor confidence is likely minimal.

Key Dates

Recommendation

This Form 4 reports a pre-scheduled sale by an executive to cover tax obligations upon vesting of restricted stock units, which is a routine event and does not typically indicate a change in the company's fundamental prospects or the executive's confidence. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Travere Therapeutics, TVTX, Form 4, Insider Sale, Christopher R. Cline, CFO, 10b5-1 plan, stock sale, restricted stock units, tax obligation